Tejaswini Kulkarni MD
Critical Care Medicine, Interstitial Lung Diseases, Occupational & Environmental Lung Disease
Associate Professor Director, Interstitial Lung Disease Program
Join to View Full Profile
1717 6th Ave SBirmingham, AL 35233
Phone+1 800-822-8816
Dr. Kulkarni is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Tejaswini Kulkarni is a pulmonologist based in Birmingham, AL, with subspecialties in Critical Care Medicine, Interstitial Lung Diseases, and Occupational & Environmental Lung Disease. She completed her fellowship in Pulmonary Disease and Critical Care Medicine at the University of Alabama Medical Center and her residency in Internal Medicine at Detroit Medical Center/Wayne State University. She is an Associate Professor at the University of Alabama Hospital and has expertise in interstitial lung diseases, particularly those associated with connective tissue diseases and idiopathic pulmonary fibrosis. Dr. Kulkarni has authored several publications in reputable journals on topics related to pulmonary fibrosis. Additionally, she is currently principal investigator/ co-investigator on clinical trials studying new therapeutics for pulmonary fibrosis.
Education & Training
University of Alabama Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2013 - 2016
Detroit Medical Center/Wayne State UniversityResidency, Internal Medicine, 2010 - 2013
Bangalore Medical CollegeClass of 2008
Certifications & Licensure
AL State Medical License 2013 - 2025
MI State Medical License 2010 - 2013
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Clinical Trials
- Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis Start of enrollment: 2023 May 15
Roles: Contact
Publications & Presentations
PubMed
- Study Design and Rationale for the PHINDER Study: Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection.Tejaswini Kulkarni, David A Zisman, Oksana A Shlobin, David G Kiely, Maral DerSarkissian
Pulmonary Therapy. 2025-09-01 - Deupirfenidone (LYT-100) in post-acute sequelae of SARS-CoV-2 with respiratory complications.Tejaswini Kulkarni, Joel Santiaguel, Raminder Aul, Mark Harnett, Julie Krop
ERJ Open Research. 2025-07-01 - Perspectives of people living with idiopathic pulmonary fibrosis: a qualitative and quantitative study.Camilla S Graham, Brianna Bisson, Jessica Shore, Emily Pardy, Frank Salisbury
BMC Pulmonary Medicine. 2025-05-08
Authored Content
- An Update in Progressive Pulmonary FibrosisOctober 2022
Press Mentions
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPFAugust 21st, 2025- PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPFAugust 21st, 2025
- What’s in a Primary Care Physician’s Toolkit for Treating Patients with Respiratory Conditions?June 20th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
